Current management of immune thrombocytopenia

Cindy E. Neunert

Research output: Contribution to journalReview articlepeer-review

66 Scopus citations


Immune thrombocytopenia (ITP) is an autoimmune-mediated condition that results from antibody-mediated destruction of platelets and impaired megakaryocyte platelet production. ITP patients exhibit severe thrombocytopenia and are at risk for significant hemorrhage. Few randomized trials exist to guide management of patients with ITP. Ultimately, each patient requires an individualized treatment plan that takes into consideration the platelet count, bleeding symptoms, health-related quality of life, and medication side effects. This article provides an up-to-date review of management strategies drawing on links between the expanding amounts of clinical trial data and associated biology studies to enhance understanding of the disease heterogeneity with regard to the complex pathogenesis and response to treatment.

Original languageEnglish (US)
Pages (from-to)276-282
Number of pages7
JournalHematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
StatePublished - Jan 1 2013

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Current management of immune thrombocytopenia'. Together they form a unique fingerprint.

Cite this